CMS identifies Medicare billing codes for combination antibody therapy
The Centers for Medicare & Medicaid Services has identified Healthcare Common Procedure Coding System for billing Medicare for the combination monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly and Co.
The Food and Drug Administration this month authorized administering the monoclonal antibodies together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy. The emergency use authorization also authorizes the treatment for patients 65 or older with certain chronic medical conditions.
Related News Articles
Headline
The AHA July 8 wrote in opposition to the 鈥淧atient Access to Higher Quality Health Care Act鈥 (H.R. 4002), which would repeal current law banning the creation鈥
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare鈥
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud鈥
Headline
The Centers for Medicare & Medicaid Services today announced it has identified a fraud scheme targeting Medicare providers and suppliers. CMS said scammers鈥
Headline
A report released June 17 by NORC at the University of Chicago, commissioned by the Coalition to Strengthen America鈥檚 Healthcare, found that patients enrolled鈥
Headline
The Centers for Medicare and Medicaid Services May 30 released a notice requesting comments on a proposed Medicare Advantage service level data collection鈥